Rejuvenate Bio, a San Diego, CA-based biotechnology firm devoted to growing novel gene therapies for power age-related illnesses, obtained $4M in grant from California Institute for Regenerative Medication (CIRM).
The corporate intends to make use of the funds to finish its IND-enabling actions for the event of RJB-0402 for the remedy of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM).
Led by Dan Oliver, CEO, and Chief Scientific Officer Noah Davidsohn, Ph.D., Rejuvenate Bio is a biotechnology firm devoted to growing novel gene therapies for power age-related illnesses. Rejuvenate Bio has constructed a gene remedy pipeline with enormous potential in power illness by using clinically validated gene targets and a supply method that ensures nicely tolerated, sturdy expression. Based on scientific analysis developed on the Wyss Institute at Harvard Medical Faculty, Rejuvenate Bio has developed therapies to deal with power age-related illness in each people and animals.
RJB-0402 is a novel systemically administered investigational AAV8 gene remedy that drives liver particular expression of FGF21 protein, concentrating on a number of key pathological drivers of DSP ACM. Because the DSP gene is simply too massive for gene alternative remedy, novel methods are wanted to deal with DSP ACM. FGF21 has recognized salutary results on cardiac dysfunction in addition to ventricular arrhythmias, adipogenesis, irritation, and fibrosis, all of that are DSP ACM hallmarks. Moreover, scientific efficacy of RJB-0402 in DSP ACM might type the premise for the remedy in different types of ACM.
FinSMEs
02/07/2024
